Search / Trial NCT06221592

Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses

Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Jan 14, 2024

Trial Information

Current as of October 07, 2024

Enrolling by invitation

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age: 6-14 years old;
  • 2. After using 1% cyclohexanone hydrochloride eye drops (Saifeijie) for ciliary muscle paralysis, binocular spherical power were within 0.00D\~-4.00D, binocular cylinder power ≤ 1.50D, the anisometropia is less than 1.50D, and the best corrected visual acuity was above 5.0;
  • 3. Within 30 days, the myopia prevention and control methods such as multifocal glasses, orthokeratology, defocusing flexible glasses, progressive glasses, atropine eye drops, red light and acupuncture and moxibustion treatment were not used;
  • 4. The subject has a willingness to receive treatment and an informed consent form is signed by their legal guardian.
  • Exclusion Criteria:
  • 1. Diagnosed constant strabismus;
  • 2. Diagnosed pathological myopia;
  • 3. Other congenital eye diseases;
  • 4. Researchers believe that the patients have other reasons that are not suitable for inclusion in the project.

About Shanghai Eye Disease Prevention And Treatment Center

The Shanghai Eye Disease Prevention and Treatment Center is a leading clinical research organization dedicated to advancing the understanding and treatment of ocular diseases. With a strong emphasis on innovation and patient-centered care, the center collaborates with various stakeholders, including academic institutions and healthcare providers, to conduct rigorous clinical trials. Its mission is to enhance eye health outcomes through evidence-based research, contributing to the global body of knowledge in ophthalmology. The center is committed to fostering a culture of excellence in clinical practices, ensuring the highest standards of safety and efficacy in all its research endeavors.

Locations

Shanghai, Shanghai, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0